Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

CerraCap Ventures Portfolio Company Totient Is Acquired by Absci

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

CerraCap Ventures, a leading early-stage Venture Fund, today announced acquisition of its portfolio company Totient by Absci for an undisclosed amount. The transaction is the second exit from CerraCap’s investment fund, CerraCap II LP.

Totient is an artificial intelligence-driven drug discovery platform that identifies and harnesses human immune responses to identify novel antibodies and their therapeutic targets.

Absci is a synthetic biology company unlocking the potential of proteins as next-generation therapeutics. This acquisition adds antibody and target discovery technology to Absci’s platform for therapeutic protein design and biomanufacturing optimization.

To date, Totient has reconstructed more than 4,500 antibodies from over 50,000 patients and has de-orphaned a collection of promising antibodies by identifying and validating their target antigens. Absci’s high-throughput single cell protein expression systems and assays offer a platform for rapidly and systematically de-orphaning the computationally derived antibody sequences in Totient’s growing library.

Both Totient and Absci share a vision to change the world by making the best medicine available to mankind. This acquisition is well aligned to build a deep library of natural human antibodies and target antigens that can be validated as new opportunities for drug development.

“We are delighted to see Totient’s platform, and their talented R&D team becoming a part of Absci. This acquisition demonstrates success of CerraCap’s ‘Sales and Scale™’ model, said Saurabh Ranjan, Founder and CEO, CerraCap Ventures.

“This highly complementary acquisition will significantly accelerate the pipeline created by Totient. We look forward to the combined team’s continued successes as they work to create breakthrough products,” added Vikas Datt, Partner CerraCap Ventures.

“Totient’s innovative work identifying disease-relevant molecules has exciting therapeutic potential,” commented Sean McClain, founder and CEO of Absci. “We believe that the combination of the Totient technology with Absci’s platform, including our Denovium AI, provides us the framework and data to enable in silico targeted drug design, and ultimately achieve our goals of making the best medicines available to patients in need.”

“Together, Absci and Totient are much more than the sum of our parts, with clear opportunities for synergy of our platforms and technologies,” said Deniz Kural, PhD, co-founder and CEO of Totient. “Our computational biology technology allows us to identify thousands of new antibodies and other categories of proteins, and with Absci, we look forward to scaling our target discovery capabilities to comprehensively de-orphan antibodies and validate new opportunities for drug development.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine